In this week’s episode, I sit down with Francisco LePort and Martin Borch Jensen, the co-founders of Gordian Biotechnology. Gordian is revolutionizing drug discovery by testing where it matters most… directly in living organisms. We discuss their groundbreaking approach of pooled in vivo screening that transforms a single organism into thousands of parallel experiments, and how this could fundamentally change our approach to studying age-related diseases.

Francisco and Martin believe that traditional anti-aging drug discovery has been ignoring the biology of aging itself. Instead of testing drugs in mice (equivalent to studying osteoarthritis in 25-year-olds), they are using actual horses that developed arthritis naturally and thus better represent aging as it actually manifests. Their early results suggest we might be on the cusp of a new era where we can finally address the root causes of multiple age-related diseases simultaneously.

This episode covers:

* Why aging research ignores actual aging biology, and how this kills drug development

* How to do the work of 10,000+ animal studies in a single experiment using gene therapy and single-cell sequencing

* How Francisco & Martin deliberately “killed their ambition” to go after aging directly

* The policy disasters strangling US biotech innovation (and why China’s gaining ground)

* How failed clinical trials waste billions in data that never gets analyzed

And in case you’re short on time, here’s a quick teaser:

Watch on YouTube; listen on Apple Podcasts or Spotify.

GUEST INFORMATION:

* Francisco LePort

* Martin Borch Jensen

* An Autocrine Signaling Circuit In Hepatic Stellate Cells Underlies Advanced Fibrosis In Nonalcoholic Steatohepatitis

* In-Vivo Pooled Screening

* Gordion Biotechnology

CONNECT WITH US:

* Website

* Substack

* YouTube

* X (Twitter)

* LinkedIn

* TikTok

Get full access to Frameshifts at frameshifts.bio/subscribe

Id. d’épisode : 1000729536312

GUID : substack:post:174952037

Date de publication : 1/10/2025 à 17:00:00